|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.10 USD | -0.88% |
|
+15.31% | - |
| 07-28 | Alamar Biosciences Launches NULISAseq Immune 340 Panel For Comprehensive Profiling Of The Immune Proteome | CI |
| 07-15 | Alamar Biosciences, Inc. Announces Board and Committee Changes | CI |
Evolution of the Average Target: Alamar Biosciences, Inc.
Evolution of the Target Price: Alamar Biosciences, Inc.
Changes in Analyst Recommendations: Alamar Biosciences, Inc.
a3b4ff0ac16d.S759fCKyZZZZ0UzkYo63iKiIvrNFDK4Y0hBcWtfYK8M.A8soJG_wLMkusyaLWujF3J68jvoMZddzvUpraJaHQ609jSwfW_EE2TyzDQ~2d7128318a7b6dbd577049e4d2882ae8
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +12.17% | |||||
| +9.27% | |||||
| +14.17% | |||||
| +27.2% | |||||
| +31.31% | |||||
| +13.48% | |||||
| +14.67% | |||||
| +12.9% | |||||
| +8.02% | |||||
| +10.94% | |||||
| Average | +15.41% | |||||
| Weighted average by Cap. | +16.06% |
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
28.10USD
Average target price
31.80USD
Spread / Average Target
+13.17%
High Price Target
35.00USD
Spread / Highest target
+24.56%
Low Price Target
28.00USD
Spread / Lowest Target
-0.36%
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| BofA Securities | |
| Leerink Partners | |
| TD Cowen | |
| JPMorgan Chase | |
| Stifel Nicolaus |
SellBuy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
28.10USD
Average target price
31.80USD
Spread / Average Target
+13.17%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALMR Stock
- Consensus Alamar Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
